The FDA on April 22, 2020, granted accelerated approval to TRODELVYĀ®, for adult patients with metastatic triple-negative breast cancer, who received at least two prior therapies for metastatic disease. TRODELVYĀ® is a product of Immunomedics, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
